Mathai Mammen, M.D., Ph.D. is leaving Merck after a little more than a year at the company to take up a position at Johnson & Johnson. The Theravance Biopharma co-founder is set to takeover from William Hait, M.D., Ph.D. as global head of R&D, freeing his predecessor to start a new role overseeing J&J’s prolific partnering operation.
Mammen will join J&J later this month and transition into his new post over the rest of the year. The formal handover is due to take place on January 1. After that, Mammen will serve as global head of R&D at J&J’s Janssen drug development arm. And Hait will start in a newly-created post that gives him oversight of the biotech incubators and network of global partnerships built up by Johnson & Johnson Innovation.
The reshuffle tasks Mammen with continuing Hait’s work to turn J&J into one of the more effective Big Pharma R&D shops. Mammen and the pipeline he oversees will need to keep up this level of performance if J&J is to hit its recently-set targets for new approvals and sales growth.
Hait is leaving Mammen with a pipeline he recently called “one of the most robust and sustainable … in the industry.” And in his new position he will continue to play a role in ensuring the pipeline is stocked with promising prospects. Hait’s new title of global head, J&J external innovation gives him responsibility for the company’s JJDC VC wing, JLABS startup incubators and the innovation centers it has set up in Boston, MA, Menlo Park, CA, London, United Kingdom and Shanghai, China.
These initiatives have enabled J&J to establish relationships with—and keep tabs on the progress of—a large number of young companies.
Appointing Hait to oversee the growing operation reiterates the unit’s importance to J&J. It is now 10 years since Hait left academia to join J&J. When Hait arrived at J&J to head up hematology and oncology R&D, the company was in the middle of consolidating the disparate teams working across its many units in those therapeutic areas. Hait oversaw that work and a period in which J&J established itself as a company to watch in oncology through drugs such as Darzalex.
Mammen’s exit deprives Merck of a SVP it only recently lured away from Theravance. Mammen left Theravance in March 2016 to take up a position at Merck that gave him a leading role in its research in key therapeutic areas, including cardiovascular and metabolic disease, immunology, oncology and immuno-oncology.
By Nick Paul Taylor
Source: Fierce Biotech
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
